- Companies
- NewLimit
NewLimit Valuation, Funding & Investors
NewLimit is valued at $3.1B as of June 2026.
Last NewLimit valuation
$3.1B
Series C · Jun 2026
Last NewLimit funding round
$435M
Series C · Jun 2026
Cumulative funding NewLimit raised
$682M
across 4 funding rounds
Key investors in NewLimit
Kleiner Perkins
Founders Fund
Abstract
Human Capital
Dimension Capital
Thrive Capital
About NewLimit
NewLimit is a South San Francisco-headquartered biotechnology company advancing epigenetic reprogramming to extend human healthspan. The firm develops therapies restoring cellular function in aging tissues, targeting diseases like neurodegeneration and cardiovascular conditions. NewLimit's platform integrates machine learning with partial reprogramming techniques to identify optimal rejuvenation protocols.
Founded
2022
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$3.1B (Jun 2026)
NewLimit Valuation
NewLimit is currently valued at $3.1B, based on its Series C in June 2026.
The $435M round was led by Founders Fund, with participation from Greenoaks, Daniel Gross, Kleiner Perkins, LAV Fund, Human Capital and 5 other investors.
NewLimit's valuation has grown 3.8x from $810M at its Series B in May 2025 to $3.1B in June 2026, across 3 priced rounds.
NewLimit valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2026 | Series C | $3.1B |
| Oct 2025 | Undisclosed stage | $1.6B |
| May 2025 | Series B | $810M |
NewLimit Funding History
NewLimit has raised a total of $682M across 4 funding rounds.
NewLimit's first fundraising round was a $72M Series A in May 2023. The most recent completed round was a $435M Series C in June 2026.
NewLimit funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2026 | Series C | Founders Fund (lead); Greenoaks; Daniel Gross; Kleiner Perkins; LAV Fund; Human Capital; Nat Friedman; Valor Equity Partners; Abstract; Thrive Capital; Quiet Capital | $435M | $3.1B | NewLimit raised USD 435M in a Series C led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. The financing lifted the company’s valuation to USD 3.1B and was announced on June 2, 2026. The capital is being used to advance NewLimit’s first age-reprogramming medicine toward human clinical trials next year. The round was framed as support for a prototype medicine designed to reverse cell age in old human liver cells, moving the company from preclinical development toward first-in-human testing. NewLimit is positioned as a longevity biotechnology company co-founded by Brian Armstrong and led by co-founder and CEO Jacob Kimmel. NewLimit is based in South San Francisco and focuses on longevity medicine and aging reprogramming therapies. Its public disclosures around this round emphasize a lead program targeting liver cells and a goal of initiating human trials in 2027. No revenue or EBITDA was disclosed in the provided materials. |
| Oct 2025 | Undisclosed stage | Lilly Ventures; Kleiner Perkins; S32; Human Capital; Abstract; Duke University; Boost VC; Dimension Capital | $45M | $1.6B | NewLimit is a biotechnology company based in South San Francisco, California, focused on radically extending human healthspan by developing medicines to treat age-related diseases through epigenetic reprogramming, which restores regenerative potential and youthful cellular function in aged and diseased cells. The company leverages functional genomics, pooled perturbation screening, and machine learning to unravel epigenetic aging biology at unprecedented scale. Co-founded by Coinbase CEO Brian Armstrong, Jacob C. Kimmel, Blake Byers, and Cathy O’Hare, NewLimit targets longevity medicines applicable even to those without classically defined diseases. On October 20-21, 2025, approximately five months after closing a $130M Series B, NewLimit raised an additional $45M in a round led by Eli Lilly and Company (Lilly Ventures), with new investors including Duke Management Co. (Duke University), Section 32 (S32), Abstract Ventures, and Boost VC, alongside existing backers Kleiner Perkins, Dimension Capital (Dimension Management), and Human Capital. The round was structured via convertible preferred shares at a post-money valuation cap of $1.6B to $1.62B, propelled by technical breakthroughs in lead programs, particularly restoring youthful liver (hepatocyte) function, positioning the company for its first clinical studies in a few years. The funding supports advancing preclinical candidates, including the first that restores multiple youthful functions in old hepatocytes, and expanding programs like a new vascular biology initiative rejuvenating endothelial cells. In 2025, NewLimit scaled its discovery engine >1000X over the field, testing more reprogramming payloads than in prior years combined, discovering 30+ payloads, launching its third therapeutic program, and reducing discovery costs >2X via AI systems. Recent hires and Scientific Advisory Board additions like Benjamin Humphreys and Matthew Breyer bolstered progress toward human trials. |
| May 2025 | Series B | Kleiner Perkins (lead) | $130M | $810M | NewLimit is a biotech company founded in 2021 by Brian Armstrong (Coinbase CEO), Jacob C. Kimmel, Blake Byers, and Cathy O’Hare, focused on developing medicines to extend human healthspan through epigenetic reprogramming of aging cells. The company targets aging as the root cause of major diseases, using large-scale genomics experiments and AI models to identify promising therapies, with programs including liver mRNA medicines and vascular rejuvenation of endothelial cells. On May 6, 2025, NewLimit raised a $130 million Series B round led by Kleiner Perkins, with participation from Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners, and existing investors like Dimension, Founders Fund, and Brian Armstrong, plus angels including John and Patrick Collison, Fred Ehrsam, Elad Gil, Joshua Kushner, Joe Lonsdale, and Garry Tan. The round boosted the post-money valuation to $810 million post-Series B, providing capital to accelerate AI-driven drug discovery, push liver therapies into clinical trials, expand R&D, and scale research capabilities. This followed a $40 million Series A, bringing total funding to around $202 million at that point. The Series B reflected rapid progress, including technical milestones achieved faster than expected, building investor confidence in NewLimit's capital-efficient plan to deliver longevity medicines. Five months later, in late 2025, NewLimit raised an additional $45 million from Eli Lilly, Duke Management, Section 32, Abstract, and insiders like Kleiner Perkins at a $1.62 billion valuation cap, driven by further breakthroughs positioning the first clinical study in the near term. |
| May 2023 | Series A | Kleiner Perkins; Fred Ehrsam; Garry Tan; Eric Schmidt; Founders Fund; Dimension Capital | $72M | - | NewLimit, co-founded in 2021 by Coinbase CEO Brian Armstrong, former GV partner Blake Byers, and stem cell scientist Jacob Kimmel, develops medicines to extend human healthspan through epigenetic reprogramming, aiming to restore youthful function in aged cells, particularly targeting liver rejuvenation and other tissues. This followed earlier commitments, including $110 million from founders over the company lifetime, bringing accessible capital to support early-stage research. NewLimit employs an AI-driven 'lab-in-a-loop' process, using in-house models to simulate and rank experimental conditions, testing promising candidates to generate proprietary data for model improvement, accelerating drug discovery from years to months. Early lab experiments demonstrated prototype treatments restoring critical liver functions like fat and alcohol metabolism in aged cells. The approach targets aging as the root of major diseases, with ambitions for a trillion-dollar market by developing drugs for dozens of cell types. Post-Series A, NewLimit raised a $130 million Series B in 2025 led by Kleiner Perkins with investors including Khosla Ventures, Nat Friedman, Daniel Gross, Human Capital, Valor Equity Partners, Founders Fund, Dimension, and angels like Patrick Collison, Elad Gil, and Garry Tan, followed by a $45 million extension in October 2025 from Eli Lilly, Duke Management, Section 32, Abstract Ventures, Boost VC, and returning backers at a $1.62 billion valuation cap to fund clinical studies. The startup competes in the longevity biotech space with peers like Retro Biosciences and Altos Labs, leveraging scaled genomics and AI for capital-efficient progress toward broad rejuvenation therapies. |
Who has invested in NewLimit?
19 investors have backed NewLimit across its funding rounds, including Kleiner Perkins, Founders Fund, Abstract, Human Capital, Dimension Capital and Thrive Capital.
Lead investors include Founders Fund and Kleiner Perkins.
NewLimit Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | May 2023 | ||
| 2 | Participant | Oct 2025 | ||
| 2 | Lead | May 2023 | ||
| 2 | Participant | Oct 2025 | ||
| 2 | Participant | May 2023 | ||
| 1 | Participant | Jun 2026 | ||
| 1 | Participant | Jun 2026 | ||
| 1 | Participant | Oct 2025 | ||
| 1 | Participant | May 2023 | ||
| 1 | Participant | Jun 2026 | ||
| 1 | Participant | May 2023 | ||
| 1 | Participant | Oct 2025 | ||
| 1 | Participant | May 2023 | ||
This data is available for Pro users. Sign up to see all 19 NewLimit investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialNewLimit Competitors
NewLimit competitors include listed companies like Tasly, Livzon Pharmaceutical Group, Jilin Aodong and Walvax Biotechnology, and private ones like MindMaze and Heyuan Biotechnology.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $8M | - | $1.5B | 187.5x | ||
| Publicly listed | $1.2B | $265M | $3.1B | 2.1x | ||
| Publicly listed | $1.8B | $477M | $3.1B | 1.6x | ||
| Publicly listed | $348M | - | $3.1B | 6.2x | ||
| Publicly listed | $361M | $73M | $3.1B | 10.8x | ||
| Private | - | - | $3B | - |
NewLimit Public Comps
NewLimit is still privately-owned, but its public comps include Tasly, Livzon Pharmaceutical Group, Jilin Aodong, Walvax Biotechnology, MBX Biosciences, Celldex Therapeutics, Hebei Changshan, uniQure, Amoytop Biotech and Neuland Laboratories.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.2B | $265M | 2.2x | 2.1x | 10.2x | 9.2x | |||
| $1.8B | $477M | 1.5x | 1.6x | 5.5x | 5.5x | |||
| $348M | - | 8.7x | 6.2x | - | 9.2x | |||
| $361M | $73M | 9.0x | 10.8x | 44.5x | 36.9x | |||
| - | ($98M) | - | - | (27.2x) | (18.5x) | |||
| $2M | ($255M) | 1520.5x | 1421.3x | (9.2x) | (7.6x) | |||
| $130M | ($28M) | 27.0x | - | (123.7x) | - | |||
| $16M | ($134M) | 143.6x | 112.7x | (17.3x) | (11.8x) | |||
This data is available for Pro users. Sign up to see all NewLimit competitors and their valuation data. Start Free Trial | ||||||||
Common questions about NewLimit
| When was NewLimit founded? | NewLimit was founded in 2022. |
| Where is NewLimit headquartered? | NewLimit is headquartered in San Francisco, CA, United States. |
| Is NewLimit publicly listed? | No, NewLimit is a private, VC-backed company. |
| What is NewLimit's valuation? | NewLimit was last valued at $3.1B in its Series C in June 2026. |
| How much funding has NewLimit raised? | NewLimit has raised $682M across 4 funding rounds. |
| What was NewLimit's last funding round? | NewLimit's last funding round was a $435M Series C in June 2026, led by Founders Fund. |
| Who are NewLimit's investors? | NewLimit's investors include Kleiner Perkins, Human Capital, Founders Fund, Abstract, Dimension Capital, Greenoaks, Daniel Gross, Lilly Ventures, Fred Ehrsam, LAV Fund and 9 others. |
| Which companies are comparable to NewLimit? | Companies comparable to NewLimit include MindMaze, Tasly, Livzon Pharmaceutical Group, Jilin Aodong, Walvax Biotechnology and Heyuan Biotechnology. |
See companies similar to NewLimit
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




